GlassScriptPhysician profile
Anand Patel
NPI 1730475047
$840.53
in general payments reported to CMS, 2019-2025
16 companies · $65.03 in 2025
The $65.03 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $131 · 2021: $141 · 2023: $18.26 · 2024: $139 · 2025: $65.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $154.21 | 2019 | |
| Neurocrine Biosciences, INC. | $107.06 | 2019-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $104.59 | 2019-2021 | |
| Ardelyx, INC. | $65.03 | 2025 | Ibsrela |
| Stryker Corporation | $62.79 | 2024 | Patient-Fitted Tmj Reconstructive Prosthesis System |
| Vanda Pharmaceuticals INC. | $62.35 | 2020-2021 | |
| Alkermes, INC. | $58.15 | 2019-2020 | |
| Neos Therapeutics, LP | $49.57 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.34 | 2021-2024 | Gattex |
| Janssen Pharmaceuticals, INC | $41.85 | 2021 | |
| Bausch Health US, LLC | $32.24 | 2019 | |
| Merck Sharp & Dohme LLC | $18.26 | 2023 | Dificid, Zinplava |
| Eisai INC. | $17.29 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.21 | 2021 | |
| Allergan, INC. | $11.59 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.